ICH stability guidelines explained, from Q1A(R2) to the draft Q1

ICH stability guidelines and what applies today

The ICH stability guidelines set the evidence used in stability testing for pharmaceuticals: a retest period for the drug substance and a shelf life for the drug product. Q1A(R2) is the main framework, supported by Q1B, Q1C, Q1D and Q1E. All five sit at Step 5 on the ICH quality guidelines register. Check regional implementation, and the scope of each text, before you build a protocol from them.

Two other names get mixed up with that set. Q1F, the old climatic zone III and IV guideline, was withdrawn in June 2006. The consolidated Q1 text is still a draft: ICH lists it at Step 3, and the FDA labels its June 2025 version a draft that is not for implementation.

The Q1 series at a glance

Status is from the ICH register, checked 27 October 2026. Regional implementation determines applicability.

ICH Q1A(R2), the core guideline

Q1A(R2) is also written as "ICH Q1A" or "ICH Q1AR2" in searches. It defines the stability data package for registering a new drug substance or drug product in the ICH regions. The EMA lists it as current, effective 1 August 2003. The FDA lists it as final guidance dated November 2003.

Per the EMA page, Q1A(R2) addresses new molecular entities and does not cover abbreviated or abridged applications, variations or clinical trial applications. But that is a limit on this text, not a free pass. Those other filings can still need stability data. Check the regional guidance for the application type you're filing.

Q1A(R2) is where the general-case long-term, intermediate and accelerated conditions sit, including when intermediate testing applies. Take the temperatures, humidities and minimum periods from the guideline text, not from a summary table on a website. Keep these apart:

• The minimum data you need at submission is not the length of the full study, and neither is the shelf life you end up with.
• Intermediate testing is not a fixed part of every protocol. The guideline ties it to specific circumstances.
• The general-case conditions are written for room-temperature products. Refrigerated, frozen and biological products, and products in semipermeable packs, follow other provisions.

The FDA's Q1A(R2) page still mentions Q1F. That's a historical reference in a 2003 document, not a sign that Q1F still applies.

ICH Q1B, photostability

Q1B is the photostability guideline for new drug substances and products. The EMA page for Q1B links the official text.

Use that text for the light-exposure conditions. Lux-hours are not lux, and UV energy is not a fixed number of exposure hours. Match the guideline's units before you set the chamber.

ICH Q1C, new dosage forms

Q1C covers new dosage forms. A new dosage form is not the same filing question as a new molecular entity under Q1A(R2). The ICH register says Q1C defines the circumstances in which reduced stability data can be accepted. Reduced data is allowed where it's justified. It isn't automatic, and the justification belongs in the dossier.

ICH Q1D, bracketing and matrixing

Q1D covers bracketing and matrixing. The ICH register describes these as reduced study designs, and the EMA Q1D page links the full text.

Neither design is a waiver. Each needs a justification, and Q1D sets the conditions. Read those conditions before you reduce the study.

ICH Q1E, evaluating stability data

ICH Q1E covers how to turn stability results into a proposed retest period for the drug substance or a shelf life for the drug product. The ICH register describes that evaluation as including extrapolation and statistics. The EMA Q1E page links the guideline.

The common mistake here is treating extrapolation as a multiplier you can always apply to your real-time data. Q1E makes it conditional, so the extrapolated period has to be argued from your own data in the submission.

Climatic zones and the withdrawal of Q1F

Q1F once gave stability conditions for climatic zones III and IV. The ICH Steering Committee endorsed its withdrawal in June 2006 and left the storage conditions for zones III and IV to the respective regions and the WHO (ICH register).

So there's no single ICH humidity condition that works for every market. If you supply climatic zones III or IV, check what each destination regulator requires. The WHO's own reference is Technical Report Series 1010, Annex 10 (2018), its guidance on stability testing of active pharmaceutical ingredients and finished products.

ICH stability guidance in the US and UK

ICH guidelines aren't one binding worldwide law. Each regulator implements them.

In the US, Q1A(R2) is final FDA guidance from November 2003. When you use FDA stability guidance, check the document status. The agency publishes both final and draft texts.

In the UK, the MHRA list of implemented ICH guidelines, updated 19 May 2026, includes Q1A(R2), Q1B, Q1C, Q1D and Q1E. The MHRA says guidelines in use before EU exit carried over as EU guidance documents referred to in the Human Medicines Regulations 2012. For a UK filing, check which of these implemented texts apply to the product and application type.

The consolidated ICH Q1 revision

ICH has a consolidated Q1 draft for stability testing of drug substances and drug products. On the ICH register the project is at Step 3. The draft text was endorsed at Step 2b on 11 April 2025. That date is not adoption, and Step 3 does not make the text final.

The FDA's June 2025 draft, content dated 24 June 2025, says the new Q1 revises Q1A(R2), Q1B, Q1C, Q1D, Q1E and Q5C. The draft's described scope includes advanced therapy products, vaccines and other complex biological products. The FDA marks the document as not for implementation.

The MHRA directory lists the existing Q1 texts, not a consolidated replacement. Don't treat a forecast adoption date as evidence that the new guideline applies. Check the final text and regional implementation notices before you change a protocol.

To check how the Q1 guidelines treat a particular product or dosage form, you can ask RegAffairs AI, which answers from the stored ICH texts with citations to each source. For the wording itself, the ICH register links every Q1 document and its current step.